Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma (Review)

  • Authors:
    • Christoph‑A. J. von Klot
    • Axel S. Merseburger
    • Markus A. Kuczyk
  • View Affiliations

  • Published online on: April 8, 2016     https://doi.org/10.3892/mco.2016.856
  • Pages: 903-908
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastatic renal cell carcinoma (mRCC) has gained a variety of therapeutic options since the introduction of targeted therapy, starting in 2007. The basic molecular mechanisms included predominantly the targeting of vascular endothelial growth factor or the inhibition of the mammalian target of rapamycin. Recently, results from two randomized controlled trials, the CheckMate‑25 and the METEOR trial, regarding therapy for RCC in the second‑line setting have been published. In the present review, the current status of second‑line therapy in mRCC is discussed, together with results from the two newly introduced substances, nivolumab and cabozantinib.
View References

Related Articles

Journal Cover

June 2016
Volume 4 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
von Klot, C.J., Merseburger, A.S., & Kuczyk, M.A. (2016). Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma (Review). Molecular and Clinical Oncology, 4, 903-908. https://doi.org/10.3892/mco.2016.856
MLA
von Klot, C. J., Merseburger, A. S., Kuczyk, M. A."Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma (Review)". Molecular and Clinical Oncology 4.6 (2016): 903-908.
Chicago
von Klot, C. J., Merseburger, A. S., Kuczyk, M. A."Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma (Review)". Molecular and Clinical Oncology 4, no. 6 (2016): 903-908. https://doi.org/10.3892/mco.2016.856